Multiple Sclerosis, Relapsing-remitting Clinical Trial
Official title:
Neuropsychological Assessments in the Multiple Sclerosis Clinic
This study is designed to identify a brief screening evaluation for MS patients that is sensitive and specific to the MS population and which correlates with the findings of our standard-of-care neuropsychological assessments.
Seventy five randomly identified patients will be evaluated. Consenting patients will
perform a Symbol Digit Modalities Test (SDMT) and have the MS Center´s standard
neuropsychological assessment performed. Tests comprising the standard assessment will be
the RBANS (Randolph, 1998), Multiscore Depression Inventory, Cross and Clock Drawings. The
selfreported Beck Depression Inventory (BDI-II) will also be obtained. An Expanded
Disability Status Scale (EDSS) will be recorded for each patient. The RBANS consists of six
scales labeled (1) Immediate Memory, (2) Visuospatial/ Constructional, (3) Language, (4)
Attention, (5) Delayed Memory, and (6) Total. Depression will be assessed by the BDI and the
MultiScore Depression Inventory.
The SDMT will be administered using standard instructions either orally or in writing. Use
of the established norms for the SDMT will be used to determine if the MS patient is
demonstrating some cognitive dysfunction. Scores less than 1.0 to 1.5 standard deviations
below mean are suggestive of cerebral dysfunction. The results will be controlled for age,
gender, and educational level.
Additionally, the results of the 75 patient assessments will be reviewed to see the
concordance between the results of the SDMT and the Neuropsychological Battery. The
association of cognitive dysfunction as identified by the SDMT will be correlated with each
of the six RBANS scales and other parameters of the cognitive aspects of the Battery.
Statistical analysis will determine the sensitivity and specificity of the SDMT in
determining abnormalities as well as an optimum cutpoint. This analysis will indicate
possible cognitive problems and the need for further testing and, potentially, intervention.
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02861014 -
A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)
|
Phase 3 | |
| Terminated |
NCT01435993 -
Multiple Doses of Anti-NOGO A in Relapsing Forms of Multiple Sclerosis
|
Phase 1 | |
| Recruiting |
NCT05964829 -
Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis
|
N/A | |
| Completed |
NCT03653585 -
Cortical Lesions in Patients With Multiple Sclerosis
|
||
| Completed |
NCT02410200 -
Study of the Effect of BG00012 on MRI Lesions and Pharmacokinetics in Pediatric Subjects With RRMS
|
Phase 2 | |
| Completed |
NCT03975413 -
Fecal Microbiota Transplantation (FMT) in Multiple Sclerosis
|
||
| Completed |
NCT05080270 -
Feasibility Study of Tolerogenic Fibroblasts in Patients With Refractory Multiple Sclerosis
|
Early Phase 1 | |
| Completed |
NCT01116427 -
A Cooperative Clinical Study of Abatacept in Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT01108887 -
An Observational Study for the Assessment of Adherence, Effectiveness and Convenience of Rebif® Treatment in Relapsing Multiple Sclerosis Patients Using RebiSmart™.
|
N/A | |
| Completed |
NCT01141751 -
An Observational Study Comparing Multiple Sclerosis International Quality of Life Questionnaire (MusiQoL) and Multiple Sclerosis Quality of Life-54 Instrument (MSQOL-54) in Relapsing Multiple Sclerosis (RMS) Patients on Long-term Rebif® Therapy
|
N/A | |
| Completed |
NCT00097331 -
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT01909492 -
Measurement of Relaxin Peptide in Multiple Sclerosis (MS)
|
||
| Completed |
NCT04121221 -
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
|
Phase 3 | |
| Withdrawn |
NCT04880577 -
Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis
|
Phase 2 | |
| Not yet recruiting |
NCT05290688 -
Cellular microRNA Signatures in Multiple Sclerosis
|
N/A | |
| Completed |
NCT04528121 -
Effect of CoDuSe Balance Training and Step Square Exercises on Risk of Fall in Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT04002934 -
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT05019248 -
Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
|
||
| Completed |
NCT04580381 -
Real World Effectiveness of Natalizumab Extended Interval Dosing in a French Cohort
|
||
| Completed |
NCT00071838 -
Zenapax (Daclizumab) to Treat Relapsing Remitting Multiple Sclerosis
|
Phase 2 |